Novo Nordisk Launches Wegovy Subscription for GLP-1 Obesity Drugs
Wegovy semaglutide tablets.
Michael Siluk | Universal Images Group | Getty Images
Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drugs, aimed at ensuring patients paying cash receive lower, “predictable” monthly prices.
Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name. Longer plans offer lower monthly prices, and the company expects people to save up to $1,200 per year on the shot and up to $600 per year on the pill, compared to paying for their single dose each month, a Novo statement said.
Patients can expect to pay flat monthly prices even if they switch to different dosages, the company said. The subscription program will be available starting Tuesday at several of Novo’s telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame and Him and himmore are expected to be added soon.
The unique offering is “an opportunity to help patients not only start but also continue therapy and help them navigate the ups and downs of some of the pricing considerations,” whether they are starting treatment or are currently taking the drug, said Ed Cinca, head of marketing and patient solutions at Novo.
The inability to take GLP-1 has long been a problem due to factors such as difficulty accessing the medication and gastrointestinal side effects. According to a 2025 study, about 65% of patients with obesity stop treatment within a year.
Wegovy subscription prices and estimated savings
Injection subscriptions (0.25, 0.5, 1.7 and 2.4 milligram doses)
- 3 months: $329 per month, savings of $240 per year
- 6 months: $299 per month, savings of $600 per year
- 12 months: $249 per month, savings of $1,200 per year
Pill subscriptions (9 and 25 milligram doses)
- 3 months: $289 per month, savings of $120 per year
- 6 months: $269 per month, savings of $360 per year
- 12 months: $249 per month, savings of $600 per year
The new program also comes at a time when Novo’s pill, which has enjoyed explosive traction since its U.S. launch in January, will face new competition from an upcoming oral GLP-1 from its main rival Eli Lilly later this year. Lilly is currently the dominant player in the branded GLP-1 market in the US with an estimated 60% share, while Novo has about 39%.
The Wegovy pill has largely reached people who have not previously taken GLP-1 injections. Therefore, it is crucial for Novo to acquire as many new patients as possible before a competitor enters the market.
At the start of Novo Nordisk’s subscription plans, paying patients can still pay $149 per month for the lower doses of the pill, which are 1.5 and 4 milligrams. However, starting in August, the 4-milligram dose costs $199 per month. Meanwhile, the recently approved 7.2-milligram dose of Wegovy will be added to the subscription program at a later date.
Cinca emphasized that patients can cancel the subscription while it is active if they no longer wish to subscribe.
“We want to help patients find a path that can help them feel comfortable about their treatment [obesity] in the long run,” he added.
Cinca said Novo doesn’t yet offer the program in its NovoCare direct pharmacy, but added that over time through that platform there would be “an opportunity to assess how that’s going and then build it out.”
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
